[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Next Life Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100623184","phase-2-effects-of-nls-133-a-potential-non-hormonal-on-demand-male-contraceptive-100623184",false,"NCT07393334","Effects of NLS-133, a Potential Non-Hormonal \"On-Demand\" Male Contraceptive","Effects of NLS-133, a Potential Non-Hormonal \"On-Demand\" Male Contraceptive, on Semen Volume and Sperm Count in Normal Men: A Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Male, age 18-55.\n2. Normal physical examination and testicular volume \\>15 cc\n3. No significant medical history that would impact the safety of the study.\n4. No current use of drugs that comprise NLS-133\n5. Normal values on baseline hematology, blood chemistry and liver function tests and serum testosterone.\n6. Normal baseline sperm parameters (semen volume \\>1.4 cc, sperm concentration \\>15 million\u002Fml, motility \\>40% and morphology \\>4%).\n7. Willing and able to comply with all study requirements and procedures.\n\nExclusion Criteria:\n\n1. History or evidence of erectile dysfunction.\n2. Inability to produce semen samples in clinic setting.\n3. Significant chronic or acute medical illness.\n4. Previous or current ethanol or illicit drug abuse.\n5. Evidence of significant underlying disease (based on results of the physical exam and the routine labs).\n6. Known infertility or hypogonadism.\n7. Planned or anticipated use of any prohibited medications during participation in the study. These include use of sex hormones for treatment, testosterone, anabolic steroids, retinoic acid (e.g., Accutane®), vitamin A, other drugs known to inhibit spermatogenesis, opioids, cocaine, methamphetamine, and\u002For the consumption of \\>4 alcoholic beverages daily.\n8. Presence of moderate-to-severe pulmonary or cardiovascular disease\n9. Known active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or COVID-19 infection.\n10. History of malignancy within 5 years before the Screening Visit, except fully treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.\n11. Known active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals during the Screening period.\n12. Any other acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with study participation in the judgment of the investigator would make the participant inappropriate for entry into the study.\n13. Participation in another investigational clinical trial within the last 30 days.\n14. Participants who live in detention on court order or on regulatory action.\n15. Related to sponsor or staff involved in the conduct of the study.",true,"MALE","18 Years","55 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","NLS-133-CLIN001 is a Phase 2a study designed to assess the safety, tolerability, and effects of NLS-133 (combination of two FDA-approved agents) compared to an active control (FDA-approved pharmacologic agent) or placebo on semen volume and sperm count in 10 in healthy men. Participants will be randomized in a crossover design to receive a single dose of NLS-133, an active control or placebo either 90 or 180 minutes prior to collection of semen. Sperm parameters measured will be count, motility and morphology. A brief questionnaire will be completed by each subject during each treatment cycle that addresses orgasm and ejaculation quality. Safety monitoring will include adverse event reporting, laboratory assessments, and vital signs.",[28,29,30],"Male Contraception","Semen Volume","Sperm Motility",[32],"Effect of NLS-133 on semen volume and semen parameters","RECRUITING","2026-01-30",{"date":36,"type":37},"2026-02-06","ACTUAL",{"date":39,"type":37},"2025-12-02",{"date":41,"type":22},"2026-05",{"name":43,"class":44},"Next Life Sciences","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100620707","phase-2-plan-a-occlusion-and-reversal-system-feasibility-study-100620707","NCT07361120","Plan A Occlusion and Reversal System Feasibility Study","Prospective, Multicenter, Single-arm, Open Label, Interventional Clinical Trial Investigating the Safety and Effectiveness of the Plan A Male Contraceptive System.","Inclusion Criteria:\n\n1. Male subject who is seeking and suitable to undergo a vasectomy as a long-term form of contraception\n2. Male subject who has voluntarily signed and dated the Institutional Review Board (IRB)\u002FEthics Committee (EC) approved informed consent form (ICF) for this study prior to initiation of any screening or study specific procedures\n3. 25 to 65 years of age at the time of consent\n4. Body Mass Index (BMI) \\\u003C31 kg\u002Fm2\n5. Good health for undergoing a vasectomy as confirmed by medical history, physical examination and clinical laboratory tests of blood and urine at the time of screening\n6. Normal semen analysis defined by the WHO Laboratory Manual for the Examination and Processing of Human Semen (6th Edition), based on the average of two semen samples ≥2 days and ≤7 days apart\n7. In the opinion of the Investigator, subject is suitable to undergo a vasectomy as a form of long-term contraception\n8. Agreement to use an effective method of contraception during the entire clinical trial until the planned vasectomy\n9. Lives in close proximity to the trial site to enable provision of fresh semen samples unless the subject agrees to provide semen samples at the trial site or laboratory\n\nExclusion Criteria:\n\n1. (On exam, has any of the following); one or both vasa not present, abnormal scrotum, large varicocele, hydrocele, filariasis or elephantiasis of scrotum, or intrascrotal mass that would make the subject not suitable for the study.\n2. Prior testicular surgery, testicular injury or prior vasectomy with vasovasostomy (vasectomy reversal)\n3. Recurrent pain with ejaculations\n4. Has known allergic reaction to sulfur-containing products or has had a prior severe allergic response to injectable or implantable devices\n5. Has local genital infections such as balanitis, scrotal skin infection, epididymitis, or orchitis, or tender (inflamed) tip of the penis, but may be enrolled after resolution of an acute infection\n6. History of prostatitis or benign prostatic hypertrophy requiring treatment\n7. Has undergone prior chemotherapy\n8. Has known current coagulopathy or other bleeding disorders\n9. Currently taking or planning to take any type of systemic medication which could affect sperm count or ejaculation (e.g., anabolic steroids, chemotherapy, alpha blocker)\n10. Subjects with cystic fibrosis\n11. Subjects with a history of inguinal hernia repair\n12. Vulnerable subjects (e.g., subjects with cognitive challenges, incarcerated, etc.)\n13. Currently participating in another study involving an investigational device or drug (or has participated in a study within the last 30 days prior to screening).\n14. Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities\n15. In the opinion of the Investigator, there are issues or concerns that may compromise the safety of the subject or confound the reliability of compliance and information acquired in this study\n16. Has any condition that, in the opinion of the Investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.","25 Years","65 Years",{"count":56,"type":22},40,[25],"Prospective, multicenter, single-arm, open label, interventional clinical trial investigating the safety and effectiveness of the Plan A Male Contraceptive System to occlude the vas deferens to block the passage of sperm and then be reversed to subsequently allow the passage of sperm through the vas deferens.",[60,61,62],"Fertility","Fertility, Male","Healthy Male Adults",[64],"Vasectomy, Fertility, Reproductive Health, Male Contraception, Vas Occlusion, No Scalpel Vasectomy,","2026-01-14",{"date":67,"type":37},"2026-01-22",{"date":69,"type":22},"2026-01",{"date":71,"type":22},"2026-09",{"name":43,"class":44},""]